Previous 10 | Next 10 |
home / stock / crrtf / crrtf news
Crescita Therapeutics Announces Measures in Response to COVID-19 Virus Canada NewsWire LAVAL, QC, March 24, 2020 LAVAL, QC , March 24, 2020 /CNW/ - Crescita Therapeutics Inc. ( TSX: CTX) ( OTC US: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, inno...
Record Annual Revenue of $22.3M Record Adjusted EBITDA of $7.0M up from $1.5M LAVAL, QC , March 18, 2020 /PRNewswire/ - Crescita Therapeutics Inc. ( TSX: CTX OTC ) ( US: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial d...
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis Canada NewsWire LAVAL, QC, Feb. 11, 2020 Primary Endpoint Achieved with High Statistical Significance LAVAL, QC...
Crescita Awarded Cannabis Research License from Health Canada Canada NewsWire LAVAL, QC, Jan. 24, 2020 LAVAL, QC , Jan. 24, 2020 /CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial dermatology company with ...
Laval, QC , Jan. 22, 2020 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treat...
Crescita to Distribute NCTF ® and ART FILLER ® Injectables in Canada LAVAL, QC , Jan. 20, 2020 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial dermatology company with manufacturing cap...
Crescita Therapeutics ( OTC:CRRTF ): Q3 GAAP EPS of C$0.00. More news on: Crescita Therapeutics Inc., Earnings news and commentary, , Read more ...
Crescita Reports 2019 Third Quarter Results Canada NewsWire LAVAL, QC, Nov. 7, 2019 Revenue up 9.9% Year-over-Year Positive Adjusted EBITDA 1 of $0.9 Million LAVAL, QC , Nov. 7, 2019 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescit...
U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis® Canada NewsWire LAVAL, QC, Nov. 5, 2019 LAVAL, QC , Nov. 5, 2019 /CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita"), a commercial dermatology company with...
Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals Canada NewsWire CALGARY and LAVAL, QC, Oct. 28, 2019 CALGARY and LAVAL, QC , Oct. 28, 2019 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial"), a Canadian licensed produce...
News, Short Squeeze, Breakout and More Instantly...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced that it has s...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has signed an exclusive distribution agreement (the “Agreement&...
Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has concluded the asset purchase agreement (the “Purchase Agree...